CHRSCoherus BioSciences, Inc.

Nasdaq coherus.com


$ 2.13 $ 0.02 (0.95 %)    

Monday, 29-Apr-2024 10:26:12 EDT
QQQ $ 432.50 $ -0.65 (-0.15 %)
DIA $ 383.40 $ 1.09 (0.29 %)
SPY $ 510.29 $ 0.03 (0.01 %)
TLT $ 88.82 $ 0.14 (0.16 %)
GLD $ 216.49 $ 0.44 (0.2 %)
$ 2.04
$ 2.11
$ 2.12 x 200
$ 2.13 x 300
$ 2.06 - $ 2.13
$ 1.43 - $ 8.22
907,176
na
192.09M
$ 1.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-15-2024 12-31-2023 10-K
2 11-06-2023 09-30-2023 10-Q
3 08-02-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 03-06-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 02-23-2022 12-31-2021 10-K
10 11-08-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 02-25-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 02-27-2020 12-31-2019 10-K
18 11-08-2019 09-30-2019 10-Q
19 08-05-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 02-28-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-08-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-08-2018 12-31-2017 10-K
26 11-06-2017 09-30-2017 10-Q
27 08-07-2017 06-30-2017 10-Q
28 05-08-2017 03-31-2017 10-Q
29 03-14-2017 12-31-2016 10-K
30 11-09-2016 09-30-2016 10-Q
31 08-09-2016 06-30-2016 10-Q
32 05-09-2016 03-31-2016 10-Q
33 02-29-2016 12-31-2015 10-K
34 11-10-2015 09-30-2015 10-Q
35 08-10-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-23-2015 12-31-2014 10-K
38 12-15-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 coherus-presents-preclinical-data-for-chs-1000-a-novel-anti-ilt4-antibody-at-the-2024-aacr-annual-meeting

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, le...

 hc-wainwright--co-maintains-buy-on-coherus-biosciences-lowers-price-target-to-11

HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price tar...

 hc-wainwright--co-reiterates-buy-on-coherus-biosciences-maintains-13-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $13 price...

 coherus-biosciences-q4-2023-adj-eps-062-misses-012-estimate-sales-91524m-miss-96400m-estimate

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of...

 earnings-scheduled-for-march-13-2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

 coherus-launches-udenyca-onbody-for-pegfilgrastim-cbqv

– Innovative design enables five-minute pegfilgrastim-cbqv delivery time –– Unique, automatic, retractable needle mechanism eng...

 baird-maintains-outperform-on-coherus-biosciences-lowers-price-target-to-9

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:CHRS) with a Outperform and lowers the price target from $1...

 truist-securities-maintains-buy-on-coherus-biosciences-lowers-price-target-to-8-report-released-on--22-january-2024

Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price targe...

 truist-securities-maintains-buy-on-coherus-biosciences-lowers-price-target-to-8

Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price targe...

 why-commscope-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal L...

 why-is-cancer-immunotherapy-focused-coherus-biosciences-stock-trading-higher-today

Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncolog...

Core News & Articles

SGMT: 94% | Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in B...

 why-coherus-biosciences-shares-are-trading-higher-by-22-here-are-20-stocks-moving-premarket

Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announc...

Core News & Articles

Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced it has entered into an agreement to divest its CIMERLI® ...

Core News & Articles

Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced it has entered into an agreement to divest its CIMERLI® ...

Core News & Articles

Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced it has entered into an agreement to divest its CIMERLI® ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION